CA2297025A1 - Compositions pharmaceutiques a base de polymeres destinees a une administration ciblee d'agents biologiquement actifs - Google Patents

Compositions pharmaceutiques a base de polymeres destinees a une administration ciblee d'agents biologiquement actifs Download PDF

Info

Publication number
CA2297025A1
CA2297025A1 CA002297025A CA2297025A CA2297025A1 CA 2297025 A1 CA2297025 A1 CA 2297025A1 CA 002297025 A CA002297025 A CA 002297025A CA 2297025 A CA2297025 A CA 2297025A CA 2297025 A1 CA2297025 A1 CA 2297025A1
Authority
CA
Canada
Prior art keywords
acid
polymeric
serotonin
construct
polymer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002297025A
Other languages
English (en)
Inventor
W. Blair Geho
John R. Lau
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SDG Technology Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2297025A1 publication Critical patent/CA2297025A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Cette invention concerne une construction polymère permettant d'administrer un agent biologiquement actif à un mammifère, laquelle construction comprend une première matrice polymère, un agent biologiquement actif contenu dans la matrice polymère et un second polymère chimiquement lié à l'agent biologiquement actif, ledit second polymère comprenant un copolymère d'acides aminés, ledit second polymère étant présent selon une dose efficace, pour réduire la fuite de l'agent actif de la construction polymère avant l'administration à l'emplacement voulu.
CA002297025A 1997-07-25 1998-07-24 Compositions pharmaceutiques a base de polymeres destinees a une administration ciblee d'agents biologiquement actifs Abandoned CA2297025A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5372997P 1997-07-25 1997-07-25
US60/053,729 1997-07-25
PCT/US1998/015457 WO1999004824A1 (fr) 1997-07-25 1998-07-24 Compositions pharmaceutiques a base de polymeres destinees a une administration ciblee d'agents biologiquement actifs

Publications (1)

Publication Number Publication Date
CA2297025A1 true CA2297025A1 (fr) 1999-02-04

Family

ID=21986168

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002297025A Abandoned CA2297025A1 (fr) 1997-07-25 1998-07-24 Compositions pharmaceutiques a base de polymeres destinees a une administration ciblee d'agents biologiquement actifs

Country Status (6)

Country Link
EP (1) EP0999855A1 (fr)
JP (1) JP2001510811A (fr)
CN (1) CN1264310A (fr)
AU (1) AU8591298A (fr)
CA (1) CA2297025A1 (fr)
WO (1) WO1999004824A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4586022B2 (ja) 2003-09-29 2010-11-24 日東電工株式会社 インビボポリヌクレオチド送達用生分解性ポリアセタール
US7674452B2 (en) 2005-03-16 2010-03-09 Nitto Denko Corporation Polymer coating of cells
US7588754B2 (en) 2005-05-10 2009-09-15 Nitto Denko Corporation Biodegradable polyacetals and methods
WO2018140834A1 (fr) * 2017-01-27 2018-08-02 Cornell University Polymères et hydrogels modifiés de manière zwitterionique
US10611857B2 (en) 2017-08-02 2020-04-07 Exxonmobil Chemical Patents Inc. Bisphenolate transition metal complexes, production and use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3360633D1 (en) * 1982-02-12 1985-10-03 Unitika Ltd Anti-cancer device
SE8804164A0 (sv) * 1988-11-17 1990-05-18 Per Prisell Farmaceutisk beredning
CA2046830C (fr) * 1990-07-19 1999-12-14 Patrick P. Deluca Systeme d'administration des medicaments comprenant une interaction entre une proteine ou une polypeptide et un polymere hydrophobe biodegradable
WO1994011015A1 (fr) * 1992-11-12 1994-05-26 Molecular Dynamics, Inc. Porteurs lipophiles a base de peptides destines a l'administration ciblee de medicaments selon un concept rationnel de fixation des medicaments
WO1995000547A1 (fr) * 1993-06-22 1995-01-05 E.I. Du Pont De Nemours And Company Composition antimicrobienne comprenant un polymere et un peptide formant des helices amphiphiles du type magainine
AU3275595A (en) * 1994-08-05 1996-03-04 Molecular/Structural Biotechnologies, Inc. Site-specific biomolecular complexes

Also Published As

Publication number Publication date
EP0999855A1 (fr) 2000-05-17
WO1999004824A1 (fr) 1999-02-04
AU8591298A (en) 1999-02-16
CN1264310A (zh) 2000-08-23
JP2001510811A (ja) 2001-08-07

Similar Documents

Publication Publication Date Title
US6063400A (en) Targeted liposomal constructs for diagnostic and therapeutic uses
EP0545913B1 (fr) Systèmes de délivrance pour agents pharmacologiques
US9526705B2 (en) Lipidated glycosaminoglycan particles and their use in drug and gene delivery for diagnosis and therapy
USRE35862E (en) Delivery systems for pharmacological agents encapsulated with proteinoids
KR101170840B1 (ko) 남용 방지성 암페타민 화합물
ES2965034T3 (es) Comprimidos resistentes al aplastamiento destinados a prevenir el uso indebido involuntario y el desvío ilícito
US20120208848A1 (en) Gacyclidine formulations
Hosny Preparation and evaluation of thermosensitive liposomal hydrogel for enhanced transcorneal permeation of ofloxacin
JP2006515620A (ja) 夜間の経口インスリン治療
CA2297025A1 (fr) Compositions pharmaceutiques a base de polymeres destinees a une administration ciblee d'agents biologiquement actifs
JP2003504312A (ja) 生物学的に活性な材料
KR20090073026A (ko) 알콜 의존증 및 코카인 의존증의 치료에 유용한, 디설피람 및 시클로덱스트린으로 형성된 포접 복합체를 포함하는 약학 조성물
MXPA99011474A (en) Polymer based pharmaceutical compositions for targeted delivery of biologically active agents
KR950009089B1 (ko) 약리학적 제제의 전달 시스템
SHANTAKUMAR et al. Enhanced Transdermal Delivery of Carvedilol Using Nanoemulsion as a Vehicle
MXPA99011581A (en) Targeted liposomal constructs for diagnostic and therapeutic uses
Hiremath Formulation and Evaluation of Microcapsules for Controlled Release of Anti Diabetic Drug by Ionotropic Gelation Technique
AU2002326564A1 (en) Lipidated glycosaminoglycan particles and their use in drug and gene delivery for diagnosis and therapy
JP2004315514A (ja) 経皮吸収製剤

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued